Phase 2 Study in Patients With MiT Tumors
This study has been completed.
First Posted: November 14, 2007
Last Update Posted: February 8, 2013
Information provided by (Responsible Party):
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been completed.|
|Study Completion Date:||February 2011|
|Primary Completion Date:||December 2010 (Final data collection date for primary outcome measure)|
|Certification or Request for Extension to Delay Results Submission:||February 6, 2013|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Wagner AJ, Goldberg JM, Dubois SG, Choy E, Rosen L, Pappo A, Geller J, Judson I, Hogg D, Senzer N, Davis IJ, Chai F, Waghorne C, Schwartz B, Demetri GD. Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial. Cancer. 2012 Dec 1;118(23):5894-902. doi: 10.1002/cncr.27582. Epub 2012 May 17.